cynarine has been researched along with indigo carmine in 6 studies
| Studies (cynarine) | Trials (cynarine) | Recent Studies (post-2010) (cynarine) | Studies (indigo carmine) | Trials (indigo carmine) | Recent Studies (post-2010) (indigo carmine) |
|---|---|---|---|---|---|
| 102 | 1 | 49 | 103 | 1 | 66 |
| 7 | 1 | 5 | 103 | 1 | 66 |
| Protein | Taxonomy | cynarine (IC50) | indigo carmine (IC50) |
|---|---|---|---|
| Aldo-keto reductase family 1 member B10 | Homo sapiens (human) | 0.13 | |
| Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | 0.3 | |
| Aldo-keto reductase family 1 member B1 | Homo sapiens (human) | 0.088 | |
| Bifunctional epoxide hydrolase 2 | Homo sapiens (human) | 2.8 | |
| Integrase | Human immunodeficiency virus 1 | 0.97 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (33.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Cornell, C; Jia, Q; Kim, TR; King, PJ; Kuan, J; Ma, G; McDougall, BR; Miao, W; Reinecke, MG; Robinson, WE | 1 |
| Al-Asri, J; Fazekas, E; Görick, C; Gyémánt, G; Lehoczki, G; Melzig, MF; Mortier, J; Perdih, A; Wolber, G | 1 |
| Ha, JH; Park, SN | 1 |
| Hostomsky, Z; King, PJ; McDougall, B; Reinecke, MG; Robinson, WE; Wu, BW | 1 |
| Li, R; Pan, S; Tao, M; Wu, T; Xu, T; Xu, X; Zhuo, Z | 1 |
| Dai, GL; Fang, ZY; Ju, WZ; Liu, F; Liu, SJ; Wu, T; Xiong, NN; Zhang, J; Zhao, Y; Zhou, L | 1 |
1 trial(s) available for cynarine and indigo carmine
| Article | Year |
|---|---|
Clinical tolerability and pharmacokinetics of Erigerontis hydroxybenzene injection: results of a randomized phase I study in healthy Chinese volunteers.
Topics: Adult; Apigenin; Chlorogenic Acid; Erigeron; Female; Glucuronates; Healthy Volunteers; Humans; Injections, Intravenous; Male; Plant Extracts; Quinic Acid; Young Adult | 2015 |
5 other study(ies) available for cynarine and indigo carmine
| Article | Year |
|---|---|
Structure-activity relationships: analogues of the dicaffeoylquinic and dicaffeoyltartaric acids as potent inhibitors of human immunodeficiency virus type 1 integrase and replication.
Topics: Anti-HIV Agents; Base Sequence; Caffeic Acids; Cell Line; Cell Survival; Chlorogenic Acid; Cloning, Molecular; DNA Primers; Drug Resistance, Microbial; HIV Integrase Inhibitors; HIV-1; Humans; Magnetic Resonance Spectroscopy; Structure-Activity Relationship; Succinates; Tartrates; Virus Replication | 1999 |
From carbohydrates to drug-like fragments: Rational development of novel α-amylase inhibitors.
Topics: alpha-Amylases; Carbohydrates; Dose-Response Relationship, Drug; Drug Discovery; Enzyme Inhibitors; High-Throughput Screening Assays; Humans; Models, Molecular; Molecular Structure; Structure-Activity Relationship | 2015 |
Mechanism underlying inhibitory effect of six dicaffeoylquinic acid isomers on melanogenesis and the computational molecular modeling studies.
Topics: Animals; Cell Survival; Dose-Response Relationship, Drug; Enzyme Inhibitors; Humans; Melanins; Melanocytes; Mice; Molecular Docking Simulation; Molecular Structure; Monophenol Monooxygenase; Quinic Acid; Stereoisomerism; Structure-Activity Relationship; Tumor Cells, Cultured | 2018 |
Dicaffeoylquinic and dicaffeoyltartaric acids are selective inhibitors of human immunodeficiency virus type 1 integrase.
Topics: Acquired Immunodeficiency Syndrome; Caffeic Acids; Chlorogenic Acid; Cinnamates; HIV Envelope Protein gp120; HIV Integrase; HIV Integrase Inhibitors; HIV Reverse Transcriptase; HIV-1; Humans; Succinates; Tartrates | 1998 |
A promising strategy for investigating the anti-aging effect of natural compounds: a case study of caffeoylquinic acids.
Topics: Aging; Animals; Binding Sites; Caenorhabditis elegans; Caenorhabditis elegans Proteins; Chlorogenic Acid; Cinnamates; Gene Expression Regulation; Insulin; Longevity; Molecular Docking Simulation; Quinic Acid; Receptor, IGF Type 1; Receptor, Insulin; Signal Transduction; Stress, Physiological | 2021 |